Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease
- 作者R. L. Wasserman; A.-M. Irani; J. Tracy; C. Tsoukas; D. Stark; R. Levy; J. Chen; S. Sorrells; R. Roberts; S. Gupta
- 卷第161卷
- 期第3期
- 印刷ISSN0009-9104
- 电子ISSN1365-2249
- 文件大小293.83KB
- 发表时间2010
- DOI10.1111/j.1365-2249.2010.04195.x
- 页码518-526
Inhibitory oligodeoxynucleotides − therapeutic promise for systemic autoimmune diseases?P. Lenert · 2005
Lactating Adenoma: A Diagnosis of ExclusionTreneth P. Baker; Jeffrey T. Lenert; John Parker; Bonnie Kemp; Anne Kushwaha; Gregory Evans; Kelly K. Hunt · 2001
Mastectomy and Contralateral Prophylactic Mastectomy Rates: An Institutional ReviewSameer Damle; Christine B. Teal; Joanne J. Lenert; Elizabeth C. Marshall; Qing Pan; Anita P. McSwain · 2011
Mastectomy and Contralateral Prophylactic Mastectomy Rates: An Institutional ReviewSameer Damle; Christine B. Teal; Joanne J. Lenert; Elizabeth C. Marshall; Qing Pan; Anita P. McSwain · 2011
What Should Be Reported in a Methods Section on Utility Assessment?Stalmeier, P. F. M.; Goldstein, M. K.; Holmes, A. M.; Lenert, L.; Miyamoto, J.; Stiggelbout, A. M.; Torrance, G. W.; Tsevat, J. · Medical Decision Making · 2001
Activation of Marginal Zone B Cells from Lupus Mice with Type A(D) CpG-OligodeoxynucleotidesBrummel, R.; Lenert, P. · The Journal of Immunology · 2005
A Public Health Grid (PHGrid): Architecture and value proposition for 21st century public healthT. Savel; K. Hall; B. Lee; V. McMullin; M. Miles; J. Stinn; P. White; D. Washington; T. Boyd; L. Lenert · 2010
Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 bindingAshman, R. F.; Goeken, J. A.; Latz, E.; Lenert, P. · International Immunology · 2011